These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35809080)

  • 1. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
    Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
    Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
    Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
    J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting.
    Strober B; Patil D; McLean RR; Moore-Clingenpeel M; Guo N; Levi E; Lebwohl M
    J Dermatolog Treat; 2022 Dec; 33(8):3178-3187. PubMed ID: 36026543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.
    Russo F; Galluzzo M; Stingeni L; Persechino S; Zichichi L; Conti A; Giofrè C; Dini V; Vispi M; Atzori L; Cattaneo A; Parodi A; Bardazzi F; Stinco G; Dapavo P; Girolomoni G; Musumeci ML; Papini M; Venturini M; Dastoli S; Di Nuzzo S; Fargnoli MC; Pagnanelli G; Bernardini N; Gambini DM; Malagoli P; Mazzatenta C; Peris K; Zalaudek I; Fabbrocini G; Loconsole F; Vassallo C; Pietroleonardo L; Prignano F; Franchi C; Offidani AM; Bonifati C; Di Lernia V; Gigante G; Bartezaghi MS; Franchi M; Ursoleo P; Aloisi E
    Clin Cosmet Investig Dermatol; 2023; 16():3561-3574. PubMed ID: 38107670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
    Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
    Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
    Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
    Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study.
    Foley P; Spelman L; Murrell DF; Mate E; Tronnberg R; Lowe PM
    Australas J Dermatol; 2022 Aug; 63(3):312-320. PubMed ID: 35816576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
    Megna M; Di Costanzo L; Argenziano G; Balato A; Colasanti P; Cusano F; Galluccio AG; Gambardella A; Lembo S; Mozzillo R; Scotto Di Luzio G; Fabbrocini G; Balato N
    Expert Opin Biol Ther; 2019 Aug; 19(8):855-861. PubMed ID: 31140882
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study.
    Zhao Y; Cai L; Liu XY; Zhang H; Zhang JZ
    Chin Med J (Engl); 2021 May; 134(11):1324-1328. PubMed ID: 33950871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study.
    Nguyen HT; Pham NTU; Tran TNA; Pham NN; Bui YT; Vu TTP
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):465-476. PubMed ID: 36472791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting.
    Strober B; Patil D; McLean RR; Moore-Clingenpeel M; Guo N; Levi E; Lebwohl M
    Dermatol Ther (Heidelb); 2022 Jun; 12(6):1351-1365. PubMed ID: 35551619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.
    Ding Y; Li W; Guan X; Liu N; Zhou Y; Li G; Wang X; Wang Z; Xiao X; Yang B; Lv C; Zhang C; Shi Y
    Clin Transl Sci; 2023 Oct; 16(10):1803-1814. PubMed ID: 37644777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.
    Chiricozzi A; Conti A; Burlando M; Odorici G; Gaiani F; Panduri S; Malagoli P
    Dermatology; 2019; 235(3):213-218. PubMed ID: 30928971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea.
    Kim BS; Kim DH; Shin BS; Lee ES; Jo SJ; Bang CH; Yun Y; Choe YB
    Ther Adv Chronic Dis; 2024; 15():20406223241230180. PubMed ID: 38415046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
    Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
    Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies.
    Augustin M; Jullien D; Martin A; Peralta C
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1174-1185. PubMed ID: 31919937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis.
    Ziolkowska-Banasik D; Hadas E; Pastuszczak M
    J Drugs Dermatol; 2024 Feb; 23(2):74-77. PubMed ID: 38306130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.